News

Olivier Vincent Joins Humanoid Global's Investment Advisory Board

Olivier Vincent Joins Humanoid Global's Investment Advisory Board

Revolutionizing Humanoid Robotics with New Advisory Member

Vancouver, BC — Humanoid Global Holdings Corp. (“Humanoid Global” or the “Company”) (CSE:ROBO, FWB:0XM1, OTCQB:RBOHF) is thrilled to announce the recent appointment of Olivier Vincent to its Investment Advisory Board. This strategic move underscores the Company’s commitment to expanding its footprint in the dynamic field of humanoid robotics and embodied AI.

Olivier Vincent's Expert Background

Olivier Vincent brings a wealth of experience to Humanoid Global. Since July 2023, he has been a member of Serve’s Board. His entrepreneurial journey includes co-founding Autozen Technology Ltd. in March 2020, where he serves as CEO. Before Autozen, Mr. Vincent had a notable tenure as CEO of Spliqs, an innovative AI technology firm. His earlier experience also includes serving as President of WeatherBug and board member of Wishpond Technologies Ltd., a recognized public company in the Canadian tech landscape.

Educational Credentials

Olivier holds advanced degrees including a Masters of Engineering in Computer Science from Ecole Nationale Superieure de Techniques Avancées Paris, and a Masters in Business and Entrepreneurship from Hautes Etudes Commerciales Paris. This strong educational foundation complements his extensive professional experience in technology and innovation.

A Vision Aligned with Future Robotics

Shahab Samimi, Chief Executive Officer of Humanoid Global, expressed enthusiasm about Olivier's addition, stating, "His proven leadership as CEO and insights from his experience with Wishpond Technologies bring invaluable expertise in AI and innovation. With this partnership, our mission to drive advancements in humanoid robotics is well-supported." Olivier shares a passion for robotics, stating, “I believe robotics is how AI grows up, and I’m committed to Humanoid Global’s mission to fund and support the companies building it.”

Roles and Responsibilities

In his capacity, Mr. Olivier will play a crucial role in various aspects of Humanoid Global’s operations ranging from opportunity identification and market intelligence to deal origination and thorough analysis of potential investments. His expertise is expected to elevate the company's strategic initiatives significantly.

Advisory Agreement Details

The advisory agreement with Olivier has a twelve-month term, commencing shortly. It allows either party to terminate the contract if necessary, ensuring flexibility in alignment with evolving business needs.

Incentives for Contributions

Notably, the Company has awarded Olivier a total of 25,000 restricted share units (RSUs), subject to CSE approval. These RSUs, which grant the recipient share ownership upon vesting, will be fully vested immediately and will expire by October 1, 2030. This incentive is part of Humanoid Global's RSU Plan and reflects the company’s commitment to aligning its strategic goals with those of its advisors.

About Humanoid Global Holdings Corp.

Humanoid Global Holdings Corp. operates as an investment issuer focusing on creating a portfolio filled with pioneering firms within the humanoid robotics and embodied AI sectors. The Company serves as a global platform, offering significant access to an actively managed portfolio that bridges various components of this emerging ecosystem, from advanced software to hardware technologies. The management team, known for its capability to scale transformative technologies, adopts a long-term, partnership-focused approach to growth.

Contact Information

For further inquiries, please get in touch with:

Shahab Samimi
Chief Executive Officer
finance@humanoidglobal.ai
info@humanoidglobal.ai
(604) 602-0001

Frequently Asked Questions

What is the significance of Olivier Vincent joining the board?

His experience in leading tech firms and strategic insights will greatly enhance Humanoid Global's objectives in AI and robotics.

What roles will Olivier Vincent fulfill in Humanoid Global?

He will advise on opportunity identification, market analysis, and strategic insights, aiding in the company’s growth initiatives.

What incentives has Olivier received for his advisory role?

He has been granted 25,000 restricted share units as part of his compensation, aligning his interests with the company's performance.

How long will the advisory agreement with Olivier Vincent last?

The advisory agreement has a term of twelve months, beginning immediately but can be terminated by either party.

What is Humanoid Global's primary focus?

The company aims to build and accelerate innovative companies in humanoid robotics and AI, facilitating their growth through capital and expertise.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

MRI Surveillance Gains Ground in Lung Cancer Care

Updated Category News Views 6

Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....

Continue Reading
GORGIE Unleashes Berry Burst: Target's New Drink Star

Updated Category News Views 5

GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...

Continue Reading
UWM Faces Class Action Deadline: Key Insights for Investors

Updated Category News Views 2

The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...

Continue Reading
PwC US and India Unite for Global Consultancy Powerhouse

Updated Category News Views 6

Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...

Continue Reading
Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Updated Category News Views 3

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...

Continue Reading
Surfing Dogs Ride Waves, Support Orphan Pets

Updated Category News Views 3

Waves, Paws, and Passion Who would've thought that dogs catching waves could also catch hearts and wallets? Well, that's exactly what's happening today at Del Mar Dog Beach with the 21st Annual Surf Dog Surf-A-Thon revving up the excitement. It's a sun-soaked day in Rancho Santa Fe, California, right in the thick of things at the longest-running dog surf competition. For...

Continue Reading
First-Time Homeowners: Unseen Pitfalls of Insurance

Updated Category News Views 2

Understanding Homeowners Insurance: Beyond the Basics Most folks diving into homeownership for the first time get caught up in the whirlwind of price tags, loans, and knick-knacks for their new place. Meanwhile, the nitty-gritty of homeowners insurance often gets tossed to the side. But take it from a weary watchdog of financial storms—it’s those details in the policy...

Continue Reading
Trial Disappointment: No Significant Gains in NSCLC

Updated Category News Views 8

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...

Continue Reading
PANDAG G1 Debuts: Revolutionizing Lawn Care Efficiency

Updated Category News Views 4

The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...

Continue Reading
Tam-Peli Steps Up in SCLC Battle: Trial Insights

Updated Category News Views 5

Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...

Continue Reading

Top 5 Most Recently Viewed Articles

HeartCore's Journey: From Nasdaq Challenges to Growth Potential

Updated Category News Views 35

HeartCore's Nasdaq Delisting Challenge HeartCore Enterprises, Inc. (NASDAQ:HTCR), a provider of enterprise software and consulting services, is currently facing a significant challenge related to its listing on the Nasdaq Capital Market. The company has received notice of non-compliance with the minimum bid price requirement, which mandates that its stock price must be at...

Continue Reading
Mitchell Capital Expands Portfolio with Optelos Acquisition

Updated Category News Views 236

Mitchell Capital's New Acquisition of Optelos Mitchell Capital, a prominent private equity firm, recently announced a significant acquisition that marks a pivotal moment for their long-term investment strategy. They have secured a controlling interest in Optelos, a distinguished provider of digital twin platforms that are tailored for enhancing critical infrastructure...

Continue Reading
Tampa Bay Lightning and Scripps Sports Forge Exciting Partnership

Updated Category News Views 247

Partnership Announcement Between Tampa Bay Lightning and Scripps Sports The Tampa Bay Lightning have officially entered into an exciting multi-year partnership with Scripps Sports. This collaboration signifies a new chapter for the Tampa Bay Lightning, expanding their reach in broadcasting and enhancing viewer engagement with National Hockey League (NHL) games. Through...

Continue Reading
Kazia Therapeutics Sets Meeting with FDA on Glioblastoma Treatment

Updated Category News Views 61

Kazia Therapeutics Prepares for FDA Meeting on Paxalisib Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, is set to meet with the U.S. Food and Drug Administration (FDA) to explore potential pathways for the registration of its innovative drug, Paxalisib, aimed at treating newly diagnosed glioblastoma multiforme (GBM). This crucial...

Continue Reading
Important Notice for Flux Power Investors on Lead Plaintiff Claims

Updated Category News Views 100

Overview of Flux Power Investor Claims Investors with concerns regarding their investments in Flux Power Holdings, Inc. (NASDAQ: FLUX) have much to consider as recent developments unfold. The national securities law firm, Faruqi & Faruqi, LLP, is actively investigating claims that could impact investor interests and is eager to assist those affected. Critical Investment...

Continue Reading